Charles Nguyen, MD
Nephrology · Eastvale, CANPI 1538400288
Payments from drug & device makers
Across 267 payments — averaging $26.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$976
- Amgen$770
- Vifor Pharma, Inc.$449
- Aurinia Pharma U.S., Inc.$444
- Livanova USA, Inc.$356
- plus $3K from 24 others
What the payments were for
- Travel & lodging$96914%
- Food & beverage$5,99285%
- Education$1202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 53 | $1,178 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $976 |
| Amgen(2 entities) | 33 | $770 |
| Vifor Pharma, Inc. | 25 | $449 |
| Aurinia Pharma U.S., Inc. | 18 | $444 |
| Livanova USA, Inc. | 5 | $356 |
| Otsuka America Pharmaceutical, Inc. | 16 | $324 |
| Bayer | 15 | $306 |
| Ardelyx, Inc. | 18 | $282 |
| Calliditas Therapeutics US Inc. | 8 | $234 |
| GSK | 8 | $177 |
| OPKO Pharmaceuticals, LLC | 10 | $173 |
| Mallinckrodt Hospital Products Inc. | 4 | $171 |
| Neurocrine Biosciences, Inc. | 3 | $170 |
| Novartis | 7 | $168 |
| Alkermes, Inc. | 4 | $151 |
| Fresenius USA Marketing, Inc. | 7 | $134 |
| Lundbeck LLC | 6 | $118 |
| Travere Therapeutics, Inc. | 6 | $117 |
| Mallinckrodt Enterprises LLC | 3 | $79 |
| Novo Nordisk | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $32 |
| Lilly USA, LLC | 2 | $31 |
| AbbVie | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,081 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 339 | $202,180 |
| VeltassaPatiromer Calcium Sorbitex | 115 | $126,978 |
| XphozahTenapanor Hcl | 37 | $107,406 |
| LokelmaSodium Zirconium Cyclosilicate | 147 | $96,309 |
| LupkynisVoclosporin | 11 | $92,433 |
| VelphoroSucroferric Oxyhydroxide | 21 | $88,670 |
| KerendiaFinerenone | 119 | $80,241 |
| RetacritEpoetin Alfa-Epbx | 51 | $29,033 |
| AuryxiaFerric Citrate | 14 | $26,916 |
| JardianceEmpagliflozin | 37 | $24,961 |
| Sevelamer Carbonate | 74 | $15,313 |
| Calcium Acetate | 49 | $9,971 |
| ProcritEpoetin Alfa | 12 | $9,544 |
| EpogenEpoetin Alfa | 28 | $8,293 |
| Cinacalcet Hcl | 33 | $5,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,178 | $298,490486 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $444 | $92,43311 claims |
| Fresenius USA Marketing, Inc.Velphoro | $134 | $88,67021 claims |
| BayerKerendia | $306 | $80,241119 claims |
| Akebia Therapeutics IncAuryxia | $17 | $26,91614 claims |
| Boehringer IngelheimJardiance | $19 | $24,96137 claims |
| Johnson & JohnsonProcrit | $32 | $9,54412 claims |
| AmgenEpogen | $770 | $8,29328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Eastvale
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.